Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.
Epicrispr Biotechnologies has raised $90.0M in total funding. The most recent round was Series C. The last funding was announced in August 2026.
Epicrispr Biotechnologies's investors include Cormorant Asset Management, Janus Henderson Investors, Sanofi Ventures, Fidelity, Octagon Capital Advisors.
Epicrispr Biotechnologies is headquartered in South San Francisco, United States.
Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.
Epicrispr Biotechnologies is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Epicrispr Biotechnologies — Funding & Investors." VCBacked, August 11, 2026, https://www.vcbacked.co/company/epicrispr-biotechnologies. Accessed September 27, 2026.
VCBacked. (2026). Epicrispr Biotechnologies — Funding & Investors. Retrieved September 27, 2026, from https://www.vcbacked.co/company/epicrispr-biotechnologies
{{cite web |title=Epicrispr Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/epicrispr-biotechnologies |website=VCBacked |access-date=September 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated